Forge Biologics

3900 Gantz Rd
Grove City
OH
43123
United States

Website: https://www.forgebiologics.com/

About Forge Biologics

Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.

42 articles about Forge Biologics

Forge Biologics Announces 7 Presentations at the Upcoming Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

5/2/2022

Forge Biologics announced today that it will deliver seven presentations during the upcoming American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting, taking place May 16-19, 2022, in Washington, D.C.
Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

4/14/2022

Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.
Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022

3/7/2022

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March.
Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

3/1/2022

Ray Therapeutics and Forge Biologics, announced a manufacturing partnership that will advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.
Forge Biologics Closes $80 Million in Additional Financing to Accelerate Planned CDMO Expansion

1/10/2022

Forge Biologics announced today 2022 manufacturing expansion plans to meet the growing demand for gene therapy manufacturing.
Forge Biologics to Present at 40th Annual J.P. Morgan Healthcare Conference

1/5/2022

Forge Biologics to Present at 40th Annual J.P. Morgan Healthcare Conference.
Forge Biologics to Present at Jefferies Gene Therapy / Editing Summit

10/27/2021

Forge Biologics announced today that Timothy J. Miller, Ph.D., Forge’s CEO, President, and Co-Founder, will deliver a company presentation at the Jefferies Gene Therapy / Editing Summit on Thursday, October 28, at 12:30 p.m. ET.
Forge Biologics to Present at 2021 Cell & Gene Meeting on the Mesa

10/11/2021

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President and Co-Founder, will discuss Forge’s robust AAV manufacturing solutions, proprietary technology advancements, and clinical development during a company presentation at Cell & Gene Meeting on the Mesa on October 12 at 5:00 p.m. PT.
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

10/4/2021

Solid Biosciences Inc. and Forge Biologics announced a partnership to advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne.
Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum

9/20/2021

Forge Biologics today announced that it has received additional designations and regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), advancing the manufacturing capabilities for its own and clients’ AAV gene therapies.
Forge Biologics Announces Key Hires in CDMO Operations and Medical Affairs, Company Presentations at World Orphan Drug Congress

8/25/2021

Forge Biologics announced today the expansion of its leadership team with two key hires in process development and medical affairs.
GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership

7/15/2021

GentiBio, Inc. announced a strategic development and manufacturing partnership today to advance GentiBio’s unique immune tolerance platform.
Forge Biologics and Case Western Reserve University Announce Gene Therapy Workforce Development Partnership

7/6/2021

Forge Biologics and Case Western Reserve University Announce Gene Therapy Workforce Development Partnership
Forge Biologics to Present at 2021 BIO Digital Conference

6/10/2021

Forge Biologics announced today that it will be delivering a company presentation at BIO Digital, hosted by the Biotechnology Innovation Organization, being held June 10-11 and 14-18, 2021.
Forge Biologics Expands Gene Therapy Leadership Team with Appointment of John Maslowski as Chief Commercial Officer

6/3/2021

Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.
Forge Biologics to Present at Jefferies Virtual Healthcare Conference

6/1/2021

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that its CEO, President and Co-Founder Timothy J. Miller, Ph.D., will present at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021. Dr. Miller will provide a company overview, detailing the company’s growth from its launch in July, 2020 with $40 million in Series A financing
Forge Biologics to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting

5/11/2021

Forge Biologics to Present at the American Society of Gene and Cell Therapy’s 24 th Annual Meeting
Forge Biologics Announces Closing of $120 Million Series B Financing

4/29/2021

Financing led by RA Capital Management with participation from Perceptive Advisors, Surveyor Capital (a Citadel company), Octagon Capital, Marshall Wace, and Drive Capital Proceeds to accelerate the expansion of the contract development and manufacturing organization (CDMO) capacity for production of cGMP adeno-associated viruses (AAV)
Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit

4/22/2021

Forge Biologics to Present at Chardan’s 5 th Annual Genetic Medicines Manufacturing Summit
Forge Biologics to Present at 2021 Virtual Cell & Gene Meeting on the Mediterranean

4/6/2021

- Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller , Ph.D., Chief Executive Officer, President, and Co-Founder will present at the annual Cell & Gene Meeting on the Mediterranean, which will be held virtually April 6-9, 2021 .